广州康婷生物医药

Guangzhou Kangting Biomedical Co., Ltd. is a pharmaceutical company based in Guangzhou, China, that focuses on the development and clinical research of small molecule drugs, including generic formulations and novel therapeutic candidates. The company is part of a pharmaceutical group associated with the Barcelo (柏赛罗) brand and the Bei family, operating primarily in the Huangpu District. Its pipeline features generic versions of Daunorubicin Hydrochloride for acute leukemia and Celecoxib for pain management, with the latter currently in bioequivalence clinical trials. Additionally, Guangzhou Kangting collaborates with international partners such as Korea Pharma to develop targeted therapies, including JAK1 inhibitors for conditions like pulmonary fibrosis.